Syros Pharmaceuticals, Inc.
(NASDAQ : SYRS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.08%109.411.1%$637.77m
GILDGilead Sciences, Inc.
1.66%75.570.9%$577.68m
AMGNAmgen Inc.
1.13%176.901.1%$506.89m
REGNRegeneron Pharmaceuticals, Inc.
1.52%388.952.7%$352.74m
BIIBBiogen Inc.
1.36%327.941.2%$335.33m
ALXNAlexion Pharmaceuticals, Inc.
2.36%115.761.9%$262.11m
VRTXVertex Pharmaceuticals Incorporated
2.34%145.861.9%$218.93m
BLUEBluebird Bio, Inc.
-0.76%182.9516.1%$207.25m
ILMNIllumina, Inc.
2.70%216.553.5%$180.07m
ALNYAlnylam Pharmaceuticals, Inc
1.56%125.5910.0%$167.77m
AAgilent Technologies, Inc.
1.64%67.601.5%$158.47m
NKTRNektar Therapeutics
3.36%56.906.1%$157.89m
INCYIncyte Corporation
0.46%96.412.5%$142.11m
BMRNBioMarin Pharmaceutical Inc.
5.07%93.024.4%$114.48m
JUNOJuno Therapeutics, Inc.
1.16%44.6813.5%$102.38m

Company Profile

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.